US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
アメリカ
NASDAQ
Arbutus Biopharma Corporation (ABUS) 銘柄情報

Arbutus Biopharma Corporation (ABUS)

4.55

0.12

(2.71%)

終了 6月19日 5:00AM

4.55

0.00

(0.00%)

取引時間後: 8:13AM

Arbutus Biopharma Corporation (ABUS) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

4.55

( 2.71% )

買値

3.52

売値

5.65

出来高

5,045,873

4.46 日の範囲 4.65

3.04 52 週間の範囲 5.10

時価総額

前日終値

4.43

始値

4.49

時刻

最終取引時間

財務取引量

US$ 22,816,057

VWAP

4.5217

平均取引量 (3 か月)

US$ 1,771,894

発行済株式数

197,537,710

配当利回り

PER

5.1

1 株当たり利益 (EPS)

0.84

歳入

191.45M

純利益

160.72M

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which... Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.arbutusbio.com

本社

Warminster, United States

設立

2026

Arbutus Biopharma Corporation is listed in the Healthcare sector of the ナスダック市場 with ticker ABUS. The last closing price for Arbutus Biopharma was US$4.43. Over the last year, Arbutus Biopharma shares have traded in a share price range of US$ 3.04 to US$ 5.10.

Arbutus Biopharma currently has 197,537,710 shares in issue. The market capitalisation of Arbutus Biopharma is US$898.80 million. Arbutus Biopharma has a price to earnings ratio (PE ratio) of 5.10.

Form 4 - Statement of changes in beneficial ownership of securities

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 8-K - Current report

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement...

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 8-K - Current report

Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

Fast Track designation has the potential to facilitate development and accelerate FDA review of imdusiran...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.43	10.4368932039	4.12	4.55	4.06	1428067	4.34565802	CS
4	0.23	5.32407407407	4.32	4.79	4.06	1564295	4.41191403	CS
12	0.09	2.01793721973	4.46	4.79	4.01	1613535	4.35898438	CS
26	-0.1	-2.15053763441	4.65	5.05	3.5	1908326	4.39472614	CS
52	1.1	31.884057971	3.45	5.1	3.04	1475294	4.29052588	CS
156	2.06	82.7309236948	2.49	5.1	1.69	1103354	3.62093136	CS
260	1.32	40.866873065	3.23	6.5	1.69	1637580	3.65434782	CS

ABUS - Frequently Asked Questions (FAQ)

What is the current Arbutus Biopharma Corporation share price?

The current share price of Arbutus Biopharma Corporation is US$ 4.55

How many Arbutus Biopharma Corporation shares are in issue?

Arbutus Biopharma Corporation has 197,537,710 shares in issue

What is the market cap of Arbutus Biopharma Corporation?

The market capitalisation of Arbutus Biopharma Corporation is USD 898.8M

What is the 1 year trading range for Arbutus Biopharma Corporation share price?

Arbutus Biopharma Corporation has traded in the range of US$ 3.04 to US$ 5.10 during the past year

What is the PE ratio of Arbutus Biopharma Corporation?

The price to earnings ratio of Arbutus Biopharma Corporation is 5.1

What is the cash to sales ratio of Arbutus Biopharma Corporation?

The cash to sales ratio of Arbutus Biopharma Corporation is 4.4

What is the registered address of Arbutus Biopharma Corporation?

The registered address for Arbutus Biopharma Corporation is 701 Veterans Circle, Warminster, Pennsylvania, 18974

What is the Arbutus Biopharma Corporation website address?

The website address for Arbutus Biopharma Corporation is www.arbutusbio.com

Which industry sector does Arbutus Biopharma Corporation operate in?

Arbutus Biopharma Corporation operates in the Biotechnology & Life Sciences sector

TradeApes

TradeApes 2月前

When $PFE settlement? Disappointed in stock response to $MRNA settlement.

iHub News

iHub News 2月前

Arbutus Shares Jump After FDA Grants Fast Track Status to Hepatitis B TherapyApril 15, 2026 10:09 AM
IH Market News
Arbutus Biopharma Corporation (NASDAQ:ABUS) shares climbed 6% on Wednesday after the company revealed it had received Fast Track designation from the U.S. Food and Drug Administration for imdusiran, its treatment candidate for chronic hepatitis B.The FDA’s Fast Track program is designed to accelerate the development and review of therapies targeting serious conditions with unmet medical needs. Drugs granted this status may benefit from more frequent interactions with the regulator and could qualify for pathways such as Accelerated Approval, Priority Review or Rolling Review, provided certain criteria are met.Arbutus said that imdusiran has delivered a functional cure in 10 patients with chronic hepatitis B in clinical trials so far, while enabling many others to remain off ongoing medication.The Warminster, Pennsylvania-based company is a clinical-stage biopharmaceutical firm focused on developing treatments for infectious diseases.Arbutus Biopharma stock price

Original: Arbutus Shares Jump After FDA Grants Fast Track Status to Hepatitis B Therapy

MWM

I'd it to the list...

I have many in that list!

db7

what a joke.. wish i never heard of abus LOL

MWM

Yep we waited for 5 years for that...

iHub News

iHub News 4月前

Moderna agrees up to $2.25 billion settlement in COVID vaccine patent disputeMarch 4, 2026 6:24 AM
IH Market News
Moderna (NASDAQ:MRNA) has reached a settlement worth up to $2.25 billion with Genevant Sciences, a subsidiary of Roivant Sciences (NASDAQ:ROIV), and Arbutus Biopharma (NASDAQ:ABUS), resolving a patent dispute tied to its COVID-19 vaccine.The agreement brings to an end multiple legal cases in the United States and internationally that alleged Moderna used lipid nanoparticle (LNP) delivery technology developed by Genevant and Arbutus in its vaccine without authorization.Analysts at William Blair described the settlement as a constructive outcome for Moderna, noting that the resolution removes a major legal uncertainty and provides the company with greater financial clarity as it approaches several late-stage oncology trial readouts expected in 2026.Moderna stock price

Original: Moderna agrees up to $2.25 billion settlement in COVID vaccine patent dispute

db7

Moderna settlement that apparently the market does not like for abus

MWM

Anyone still here? Something might be about to break. ABUS up on big volume while MRNA is down on big volume. Who has the scoop?

georgie18

georgie18 8月前

ABUS...$4.48...🥳

georgie18

Member Level
Re: None

Thursday, October 09, 2025 5:58:31 PM

Post#
701895
of 702626
ABUS...$4.31...🥳...https://schrts.co/QRtDFbBZ ...Cup N Handle setting up here...

georgie18

georgie18 8月前

ABUS...$4.31...🥳...https://schrts.co/QRtDFbBZ ...Cup N Handle setting up here...

db7

Monksdream

Monksdream 1年前

ABUS, recent 52 week low

db7

https://www.globenewswire.com/news-release/2025/03/03/3035733/14025/en/Genevant-Sciences-and-Arbutus-Biopharma-Initiate-International-Patent-Infringement-Enforcement-Actions-Against-Moderna.html

db7

some scenarios(imo?):

BEST case scenario: A letter of intent to completely divest of the HBV assets 'prior' to Pfizer Markman ruling for a respectectable amount; this would put a solid floor at the purchase price and leave risk-free upside into Pfizer Markman result. HUGE cherry on top if result leaned heavily our way. This 'could be' a scenario where we see $15+ ??

WORST case scenario: Pfizer Markman comes out prior to HBV deal and leans towards Pfizer. Maybe temporarily drops share price to $2.50 to $2.75(?) Then we seem to be weak and lose some of our HBV bargaining power(?)

Timing?

HBV:
Based on commentary when the new directors were announced, 'possibly' hear about an HBV transaction prior to the annual general meeting in mid-March(?)
.. BUT obviously could drag out.... 'should be' this year????

Pfizer Markman ruling:
Supposedly 1st half 2025 but in looking at the Judge's past Markman rulings it could be ~8 months'ish???

Moderna Summary Judgement in regards to Gov't contracts..etc:
Q2/Q3 if i recall correctly

Moderna Hearing:
Sept 2025

Qilu payment:
1st half 2025

Would LOVE to have a bunch of solid wins in 1st half 2025....

db7

tell me about it!?! ... and of course i keep rolling calls on her............. someday?!? 'i think' this will at minimum double this year with max downside to around $2.50ish 'if' they completely lost on pfizer markman(?)

MWM

long wait on this one. Maybe some day!

db7

"The Company will temporarily pause participation in investor meetings and conferences while the new board and management team reviews development plans and strategic options for its hepatitis B programs."

db7

https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-announces-changes-board-directors-and-appointment

db7

Whitefort message and adding: https://www.sec.gov/Archives/edgar/data/1447028/000092189525000560/xslSCHEDULE_13D_X01/primary_doc.xml

db7

ROIV filed sc-13d yesterday: "Roivant and its representatives are evaluating potential near-term changes to the composition of the board of directors and management of the Issuer. Roivant's representatives may also be engaged in discussions related to such potential changes in the board of directors and management of the Issuer with other shareholders of the Issuer. "

Monksdream

Monksdream 1年前

MWM

ABUS made it on mad money tonight, the ultimate spec!

https://www.cnbc.com/2025/01/13/cramers-lightning-round-arbutus-biopharma-is-the-ultimate-spec.html

MWM

I'll look now 👍🏽

db7

MWM see today’s update. Qilu milestones coming and no more atm

Pfizer Markman results ‘soon’. Assuming they are positive we should have liftoff. ATM program killed the Moderna Markman last year and won’t be used during Pfizer results it sounds like

Now to just get a decisive victory!?!???

db7

nice new Blackrock 13F: https://stocktwits.com/bs010101/message/592459944

db7

2 days to AASLD...

mick

db7

2 late breakers for AASLD: https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-announces-multiple-abstracts-highlighting-imdusiran-data

mick

https://www.stockscores.com/charts/charts/?ticker=ABUS

mick

ABUS
Arbutus Biopharma Corporation
4.5488
0.0388 (0.86%)
Volume: 1,579,948
Day Range: 4.39 - 4.56
Last Trade Time: 7:46:00 PM EDT

db7

breaking out; dare i say 'someone' knows 'something'(?)

db7

ARBUTUS PHARMA CORP. et al v. PFIZER INC. et al "Please take notice that an in-person Markman Hearing is hereby scheduled for 12/18/2024 at 10:30AM in Trenton- Courtroom 4W. So Ordered by Judge Zahid N. Quraishi on 9/3/2024. (kas)"

db7

Monksdream

Monksdream 2年前

DewDiligence

DewDiligence 2年前

ABUS pares pipeline–reduces workforce 40%:

https://finance.yahoo.com/news/arbutus-reports-second-quarter-2024-113000099.html

The company’s will focus on clinical development of Imdusiran regimens for HBV, but will terminate research on new HBV compounds.

Oddly (for the reason mentioned at the bottom of #msg-174556022), ABUS opted to retain its oral PD-1 program.

Rockurstocks

Rockurstocks 2年前

Not for long! $ABUS$

Monksdream

Monksdream 2年前

mick

ABUS
Arbutus Biopharma Corporation
3.645
-0.135 (-3.57%)
Volume: 449,700
Day Range: 3.645 - 3.845
Last Trade Time: 2:29:04 PM EDT

Monksdream

Monksdream 2年前

ABUS new 52/week high

db7

db7

https://www.sec.gov/Archives/edgar/data/1447028/000089542124000390/ArbutusABUS.txt

db7

New Presentation: https://investor.arbutusbio.com/static-files/f33bde13-92b8-48c4-a40e-36cf6dd25852

db7

Poster for EASL https://www.arbutusbio.com/wp-content/uploads/2024/06/WED-371-Yuen-et-al-AB-729-201-IFN-poster-EASL-2024_FINAL.pdf

mick

ABUS
Arbutus Biopharma Corporation
3.341
-0.019 (-0.57%)
Volume: 534,638
Day Range: 3.30 - 3.385
Last Trade Time: 12:14:00 PM EDT
Delayed by 15 minutes

db7

EASL June 6-8th:
https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-present-imdusiran-data-easl-congress-2024

"
HBsAg = LLOQ (lower limit of quantification) with detectable anti-HBs was observed at end-of-treatment in 28% of subjects who received 4 or 6 doses of imdusiran plus 24 weeks of IFN
"

db7

Arbutus is waking up a little following yesterday's Motion to Dismiss with Acuitas:
https://www.law360.com/ip/articles/1839088/judge-tosses-acuitas-covid-biotech-ip-suit-

other important events of late include:

1) company stating they have stopped their ATM and don't see a need to use it the rest of this year

2) the Markman order against Moderna that went in their favor:
https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-biopharma-announces-claim-construction-ruling-its

3) Activist becoming involved:
https://www.morningstar.com/news/business-wire/20240517970994/whitefort-capital-publishes-open-letter-to-arbutus-biopharma-shareholders-outlining-paths-to-maximize-value

db7

issue here, now, might be too many open $3 calls? will mm's hold her under....

db7

mgmt killed this stock with that ATM; imo, used in a suspicious manner... ie: they put a lid on her on the markman order release at $3ish .. WHY would you do that? They could have raised same money at double the price

MWM

db7

https://www.businesswire.com/news/home/20240517970994/en/

Arbutus Biopharma

Ab Carval Credit Opportu...

Sensata Technologies

Oxford Technology 4 Vent...

Eagle Ford Oil and Gas (EM)

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。